TAKHZYRO sol inj 300 mg/2ml stylo prérempli
7680701500011
CH-70150
B06AC05
1 / 3
google
Details
- Product number
- -
- CPT
- -
- Packaging group
- -
- Unit
- -
Official Swissmedic V2 data
Additional information from the official database
Detailed composition
| Substance | Quantity | Type | Category |
|---|---|---|---|
|
lanadelumabum
|
300.0 MG | Substance | Wirkstoff (Principe actif) |
|
dinatrii phosphas dihydricus
|
- | Substance | HNIDK |
|
acidum citricum monohydricum
|
- | Substance | HNIDK |
|
histidinum
|
- | Substance | HNIDK |
|
natrii chloridum
|
- | Substance | HNIDK |
|
polysorbatum 80
|
- | Substance | HNIDK |
|
aqua ad iniectabile
|
- | Substance | HNIDK |
|
natrium
|
6.91 MG | Substance | HBESI |
Reimbursement information
Public price
CHF 9964.85
Specialties list
Yes
Generic
No
Reimbursement limitation
SL addition date:
01/06/2026
Authorization holder
Takeda Pharma AG
8152 Opfikon
Authorization information
- Swissmedic authorization number
- 70150
- Drug name
- TAKHZYRO, Injektionslösung im Fertigpen
- Galenic form
- INLFP
- ATC Code
- B06AC05
- Authorization status
- Z
- Dispensation category
- B
- First authorization
- 19/02/2026
- Authorization expiration date
- 18/02/2031
- IT number
- 02.99.0.
- Domain
- Human medicine
Packaging details
- Description (FR)
- TAKHZYRO sol inj 300 mg 1 pce
- Description (DE)
- TAKHZYRO Inj Lös 300 mg 1 Stk
- Market launch
- 19/02/2026
- Narcotic (BTM)
- No